|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Indeed, both aberrant methylation of the RASSF1A promoter and hrHPV infection are often observed in cervical carcinomas.
|
26320446 |
2015 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The observed aberrant methylation frequencies of the RASSF1A and APC gene promoters indicate that an accumulation of epigenetic events at these specific TSG promoters may be associated with the malignant transformation of benign cystadenomas and LMP tumours to carcinomas.
|
23055343 |
2012 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Significantly, more frequent RASSF1A hypermethylation was found in Type I endometrioid carcinomas than Type II carcinomas (p = 0.049).
|
18404674 |
2008 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
High-frequency RASSF1A methylation in premenopausal carcinomas and an increased frequency in endometrial hyperplasia indicate that this may be an early event in endometrial carcinogenesis.
|
17170014 |
2007 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Methylation of the RASSF1A promoter (region 1) was detected in 22.7% (5/22) of carcinomas, 12.5% (1/8) of adenomas, and 0% (0/26) of normal gallbladder epithelia (P = 0.025).
|
18182852 |
2007 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
(a) Benign and malignant salivary tumors differed in the frequency and pattern of gene methylation; (b) high-grade carcinomas were significantly methylated compared with low-grade phenotypes; (c) RASSF1 and RARbeta2 were highly methylated in malignant tumors and can be targeted for therapy; and (d) methylation pattern may serve as a diagnostic and biological marker in assessing these tumors.
|
17189407 |
2006 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The RASSF1A promoter hypermethylation was frequently found in borderline tumors and carcinomas, suggesting that RASSF1A promoter hypermethylation may be a useful molecular marker for the early detection of ovarian tumors.
|
16315018 |
2006 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
Methylation of RASSF1A was present in 16 of 31 (52%) sporadic MSI colorectal and 11 of 25 (44%) MSI gastric carcinomas, and in six of 20 (30%) HNPCC carcinomas.
|
16007118 |
2005 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We studied the association between ten nucleotide polymorphisms of RASSF1A and the risk of breast cancer in 178 cases with tumorous alterations of mammary tissue (including 141 carcinomas and 37 fibroadenomas) and 70 controls by SSCP and sequencing.
|
15942659 |
2005 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In this study, we investigated the methylation status of the RASSF1A promoter in association with 3p LOH and K-ras mutations in 48 flat colorectal tumors (39 early carcinomas and nine intramucosal high-grade dysplasias).
|
15480433 |
2004 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To address the aberrant promoter methylation profiles of MSI-H gastric carcinomas, promoter methylation of six genes (hMLH1, p16(INK4A), E-cadherin, Rb, RASSF1A, and VHL) and CpG island methylator phenotype (CIMP) were explored in 36 MSI-H gastric carcinomas and the results were compared with those of 43 microsatellite-stable (MSS) gastric carcinomas.
|
12692837 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
RASSF1A inactivation and K-ras activation are mutually exclusive events in the development of certain carcinomas.
|
12647816 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data imply that the presence of HPVs in cervical carcinomas alleviates the requirement for RASSF1A inactivation and suggests that these two events may engage the same tumorigenic pathway.
|
12702579 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
There is limited analysis of inactivation of RASSF1A in tumors other than carcinomas.
|
12670917 |
2003 |
|
Carcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In UTC, which belongs to the most aggressive carcinomas in humans, the most common combined inactivation of RASSF1A and p16 was detected.
|
12097277 |
2002 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
We found complete methylation of the RASSF1A promoter in 63% of primary microdissected prostate carcinomas (7 of 11 samples).
|
12067994 |
2002 |
|
Carcinoma
|
0.100 |
PosttranslationalModification
|
group |
BEFREE |
The CpG island of the novel tumor suppressor gene RASSF1A is intensely methylated in primary small cell lung carcinomas.
|
11429703 |
2001 |
|
Carcinoma
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Subsequently methylation of a CpG island in the promoter region of RASSF1A was demonstrated in a majority of small cell lung carcinomas and to a lesser extent in non-small cell lung carcinomas.
|
11709729 |
2001 |
|
Carcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Compared with normal bladder tissues, loss or significant reduction of RASSF1A was identified in 62% (34 of 55) of primary bladder carcinomas and 10 (83%) of 12 matched sets showed tumor-specific alteration of RASSF1A expression.
|
11559536 |
2001 |